保诚 PUK

Anil Wadhwani will be appointed to the board as Chief Executive Officer with effect from 25 February 2023. Anil Wadhwani is a global financial services leader with more than 30 years' experience, predominantly in Asia, combining strategic vision and execution in some of the world's biggest companies. Most recently, as CEO of Manulife's Asia region, he successfully grew and transformed its diversified and multi-channel business with significant market share gains in many key markets and making it the company's largest source of core earnings. Mr Wadhwani also has significant and proven digital experience, having driven the modernisation of technology platforms across 13 markets in Asia in his previous role. Prior to this he spent 25 years with Citi in Asia Pacific, Europe, the Middle East, Africa and the US, in a number of consumer financial services roles. Mr Wadhwani was born in 1968 and educated in Mumbai and has worked in Mumbai, Singapore, London, New York and most recently for nearly five years in Hong Kong. He will be based in Hong Kong, where he currently resides.

Jeremy brings to the Board substantial leadership experience in the financial services sector across Asia. He has extensive technical audit and risk management skills and experience, particularly with regard to multinational companies. Jeremy was formerly the Chairman of Global Financial Services at KPMG International having previously been in charge of its UK Financial Services Practice and held roles including Head of Financial Services KPMG Europe, Head of Clients and Markets KPMG Europe and CEO of KPMG’s UK consulting business. Jeremy served as a member of the Group Management Board of Atos Origin and as Head of its UK operations. Jeremy also served on the board of the UK Commission for Employment and Skills. Key current external appointments > UBS Group AG/UBS AG (Audit Committee Chair, Senior Independent Director, Vice-Chair) > The Productivity Group > The Kingham Hill Trust

George has considerable operational expertise in financial services, following a career spanning 40 years in the insurance industry including across the Asia Pacific region. From 2014 to 2019 he was the regional Chief Executive Officer of Allianz’s Asia Pacific business, having previously held a range of senior roles for Allianz including Chief Executive of Allianz Italy, Chief Executive of Allianz Turkey, Global Head of Change Programmes for the Allianz Group, General Manager of Allianz Malaysia, Allianz Australia and New Zealand. He also previously sat on the Financial Advisory Panel of the Monetary Authority of Singapore from 2015 to 2019. Mr Sartorel began his career at Manufacturers MutualInsurance in Australia. Key current external appointments > Insurance Australia Group Limited

Mark Saunders will be appointed to the board as non-executive director with effect from 01 April 2024. Mr Saunders has extensive knowledge of the insurance industry and Asia markets having been employed in the industry for 35 years, with the last 30 of those based in Hong Kong and is a qualified actuary. From 2014 to 2022 he served on the executive committee of AIA Group Ltd as Chief Strategy and Corporate Development Officer. He previously spent over 16 years at Tillinghast (now Willis Towers Watson) where he led a large number of actuarial appraisal value assessments of insurers across 20 markets in Asia Pacific, ultimately becoming leader of the Hong Kong business.

Arijit Basu has been appointed to the board as non-executive director with effect from 01 September 2022. Mr Basu has extensive experience in the banking and insurance industries in India. He was Managing Director and CEO of SBI Life Insurance Company, one of India's leading life insurers, from 2014 until 2018 and took it public in 2017. He has held senior positions at State Bank of India (SBI Bank) in a career spanning nearly 40 years. He is also a member of the Academic Advisory Council of the College of Supervisors established by the Reserve Bank of India (RBI) to advise the regulator on supervisory colleges. Mr Basu was appointed chairman of the Board of HDB Financial Services Ltd in June 2021, a leading financial services firm and subsidiary of HDFC Bank Ltd. He is a senior advisor to leading firms, including Ares SSG, AZB & Partners and Deloitte Shared Services India LLP. In January 2021 he was appointed by the RBI as a member of its Academic Advisory Council. He is also a director of Peerless Hospitex Hospital and Research Center Ltd. Mr Basu holds an Honours degree in Economics and a Master's degree in History from the University of Delhi. External appointments: Non-Executive Chairman of the Board of IndusInd Bank Limited.

Claudia Suessmuth-Dyckerhoff has been appointed to the board as non-executive director with effect from 01 January 2023. Dr Suessmuth-Dyckerhoff has a deep and broad knowledge of the healthcare services sector and health technology across China and the broader Asia-Pacific region. She has spent much of her career based in Shanghai and, more recently, in Hong Kong and has worked with healthcare providers, governments, insurers, pharmaceuticals and medical device companies. Dr Suessmuth-Dyckerhoff joined the global consultancy firm McKinsey & Partners in 1995 and worked in a number of senior roles. She was responsible for helping to build the firm's healthcare Services and Systems sector in Asia Pacific, working with the Chinese Ministry of Health to help develop their views on China's national healthcare systems. Much of the client work during this period involved transformation through technology, digital and data and her board experience in recent years has helped her develop valuable insights around the implementation of this in healthcare services. She has experience in China having been based in Shanghai for nearly 15 years and in Hong Kong for a further two years. Dr Suessmuth-Dyckerhoff has a portfolio of non-executive directorship roles, mostly in the healthcare and healthcare technology sectors. She is currently a non-executive director of the following listed companies: Ramsay Health Care Ltd, Clairant AG and Hoffman-La Roche AG. She is also a non-executive director of Huma Therapeutics Ltd, QuEST Global Services Private Ltd and an advisor to aMoon Ventures Y.SH. Ltd. Dr Suessmuth-Dyckerhoff holds a Ph.D in Business Administration from the University of St. Gallen.

Dr Guido Furer has been appointed to the board as non-executive director with effect from 01st July 2025. Dr Furer has over three decades of international experience across financial services. He began his career with Swiss Bank Corporation/O'Connor & Associates in options trading and in its Capital Markets division in Chicago, New York, London and Zurich. In 1997 he joined Swiss Re, where he held various positions before being appointed Group Chief Investment Officer and member of the Group Executive Committee in 2012, heading up Group Asset Management until his retirement in March 2023. Between 2019 and 2023, Dr Furer served as Country President, Swiss Re Switzerland, and held the roles of Chair of Swiss Re's Strategic Council, Zurich Pension Fund, and Trustee of the Swiss Re Foundation. During his time at Swiss Re Dr Furer served on the boards of a number of subsidiary entities and, from 2018 to 2022, as a non-executive director of pan-Asian insurer FWD Group, where he chaired the Group Risk Committee. In addition, he played a significant role in the establishment of the UN-enabled Net-Zero Asset Owner Alliance. Following his retirement, Dr Furer became a member of the board of insurance and banking group Baloise Holding AG in April 2024, becoming Chair of the Risk & Investment Committee in April 2025. Dr Furer has a master's degree in Economics and a doctorate in Financial Risk Management from the University of Zurich, where he is now Chair of the Advisory Board of the Department of Finance.

Sir Douglas retired as Group Chair of HSBC Holdings plc in September 2017, having been appointed to that role in 2010. For 15 years prior to that, he was HSBC's Group Finance Director, having joined from KPMG where he was a partner. Sir Douglas has been Chair of Aberdeen Group Plc since January 2019 and will be stepping down on 28 April 2026, and Chair of IP Group plc since November 2018 and will be stepping down from this role in June 2026. He was also previously a non-executive director at BP plc from 2005-2011, Chairman of the Institute of International Finance from June 2012 to December 2016, and a member of both the Mayor of Beijing's and the Mayor of Shanghai's International Business Leaders' Advisory Boards. Sir Douglas received his CBE in 2006 and knighthood in 2018 recognising his services to the finance industry. Sir Douglas is a member of the Institute of Chartered Accountants of Scotland. Relevant skills and experience for Prudential– Senior boardroom experience including extensive experience leading global financial institutions. Deep knowledge of Asia, including Prudential’s key markets, and understanding of global finance. Listed company directorships– Aberdeen Group plc (Chair), IP Group plc (Chair). Other key appointments– The Royal Marsden NHS Foundation Trust and Charity (Chair), Monetary Authority of Singapore, Advisory Council (Member), Institute of International Finance (Board Member). Douglas Flint took on the role of Chair of the Board at the conclusion of the AGM.